TriangleNCT03412565 · CITED IN SOURCE DOCUMENTS
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2025-04-29
The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR)
D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response
Maximum Observed Serum Concentration (Cmax) of Daratumumab
Percentage of Participants With Infusion-Related Reactions (IRRs)
D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response
D-VRd Cohort: Overall Response Rate (ORR)
Percentage of Participants With CR or Better Response
D-VMP, D-Rd and D-Kd Cohorts: Duration of Response (DOR)
Percentage of Participants With Anti-Daratumumab Antibodies
Percentage of Participants With Anti-rHuPH20 Antibodies
D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With Minimal Residual Disease (MRD) Negative Rate
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Multiple myeloma diagnosed according to the International Myeloma Working Group (IMWG) diagnostic criteria * Measurable, secretory disease as defined by any of the following: 1. Serum monoclonal paraprotein (M-protein) level greater than or equal to (\>=) 1.0 gram per deciliter (g/dL); or 2. Urine M-protein level \>= 200 milligram per 24 hours (mg/24 hours); or 3. Light chain multiple myeloma (MM), for participants without measurable disease in the serum or urine: serum Immunoglobulin (Ig) free light chain (FLC) \>= 10 mg/dL and abnormal FLC ratio * Meets one of the sets of the following criteria: 1. For Daratumumab + bortezomib + lenalidomide + dexamethasone (D-VRd) and Daratumumab + bortezomib + melphalan + prednisone + dexamethasone (D-VMP) regimen: newly diagnosed myeloma 2. For Daratumumab + lenalidomide + dexamethasone (D-Rd) and Daratumumab + Carfilzomib + Dexamethasone (D-Kd) regimen: relapsed or refractory disease 3. D-Kd cohort: Participants must have received only 1 prior line of therapy for MM which included at least 2 consecutive cycles of lenalidomide therapy * Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0, 1, or 2 * During the study, during dose interruptions, and for 3 months after receiving the last dose of any component of the study treatment, a female participant must agree not to donate eggs (ova, oocytes) and male participants of reproductive potential must not donate semen or sperm during the study, during dose interruptions, or for 3 months after the last dose of any study drug Exclusion Criteria: * History of malignancy (other than MM) unless all treatment of that malignancy was completed at least 2 years before consent and the participant has no evidence of disease further exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion, that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years * Exhibits clinical signs of meningeal involvement of MM * Either of the following: a) Chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) is less than (\<) 50 percentage (%) of predicted normal b) Moderate or severe persistent asthma, or a history of asthma within the last 2 years, or currently has uncontrolled asthma of any classification c) For D-Kd cohort: Known infiltrative pulmonary disease or known pulmonary hypertension * Any of the following: a) Known to be seropositive for human immunodeficiency virus; b) Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen \[HBsAg\]). Participants with resolved infection (participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen \[Anti-HBc\] and/or antibodies to hepatitis B surface antigen \[Anti-HBs\]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are polymerase chain reaction (PCR) positive will be excluded * Known to be seropositive for hepatitis C (Anti-HCV antibody positive or HCV-RNA quantitation positive) except in the setting of a sustained virologic response \[SVR\], defined as aviremia at least 12 weeks after completion of antiviral therapy * For D-Kd cohort only: Transthoracic echocardiogram showing left ventricular ejection fraction (LVEF) \<40%; uncontrolled hypertension, defined as an average systolic blood pressure greater than (\>)159 millimeters of mercury (mmHg) or diastolic \>99 mmHg despite optimal treatment
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m\^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.
- intervention Names
- Drug: Daratumumab
- Drug: Bortezomib
- Drug: Lenalidomide
- Drug: Dexamethasone
- label
- Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)
- type
- EXPERIMENTAL
- description
- Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m\^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m\^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m\^2 orally on Days 1 to 4 of cycles 1 to 9.
- intervention Names
- Drug: Daratumumab
- Drug: Bortezomib
- Drug: Melphalan
- Drug: Prednisone
- label
- D + Bortezomib + Melphalan + Prednisone (D-VMP)
- type
- EXPERIMENTAL
- description
- Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.
- intervention Names
- Drug: Daratumumab
- Drug: Lenalidomide
- Drug: Dexamethasone
- label
- Daratumumab + Lenalidomide + Dexamethasone (D-Rd)
- type
- EXPERIMENTAL
- description
- Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days) then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; Carfilzomib 20 mg/m\^2 intravenously (IV) on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or IV weekly for Cycles 1-9 then on Days 1, 8, 15 of each cycle for Cycles 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study.
- intervention Names
- Drug: Daratumumab
- Drug: Dexamethasone
- Drug: Carfilzomib
- label
- Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- D + Bortezomib + Melphalan + Prednisone (D-VMP)
- Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
- Daratumumab + Lenalidomide + Dexamethasone (D-Rd)
- Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)
- description
- Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
- name
- Daratumumab
- type
- DRUG
- arm Group Labels
- D + Bortezomib + Melphalan + Prednisone (D-VMP)
- Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)
- description
- Bortezomib will be administered as 1.3 mg/m\^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
- name
- Bortezomib
- type
- DRUG
- arm Group Labels
- Daratumumab + Lenalidomide + Dexamethasone (D-Rd)
- Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)
- description
- Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
- name
- Lenalidomide
- type
- DRUG
- arm Group Labels
- Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
- Daratumumab + Lenalidomide + Dexamethasone (D-Rd)
- Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)
- description
- Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
- name
- Dexamethasone
- type
- DRUG
- arm Group Labels
- D + Bortezomib + Melphalan + Prednisone (D-VMP)
- description
- Melphalan will be administered as 9 mg/m\^2 orally in Cycles 1 to 9.
- name
- Melphalan
- type
- DRUG
- arm Group Labels
- D + Bortezomib + Melphalan + Prednisone (D-VMP)
- description
- Prednisone will be administered as 60 mg/m\^2 orally in cycles 1 to 9.
- name
- Prednisone
- type
- DRUG
- arm Group Labels
- Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
- description
- Carfilzomib will be administered as 20 mg/m\^2 IV on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
- name
- Carfilzomib
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 265
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- ORR was defined as the percentage of participants who achieved partial response (PR) or better according to international myeloma working group (IMWG) criteria. IMWG criteria for PR: greater than or equal to (\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to less than (\<) 200 milligrams (mg) per 24 hours, If the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.
- measure
- D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR)
- time Frame
- Up to 2 years 3 months
- description
- VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response \[sCR\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.
- measure
- D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response
- time Frame
- Up to 2 years and 3 months
- secondary Outcomes
- description
- Cmax was defined as maximum serum concentration observed following daratumumab administration. Each cycle for: D-VRd cohort is of 21 days, D-VMP cohort is of 42 days and D-Rd and D-Kd cohorts is of 28 days. Each cohort have a treatment period of 84 days.
- measure
- Maximum Observed Serum Concentration (Cmax) of Daratumumab
- time Frame
- D-VRd: Day 4 of Cycles 1 and 4 and post treatment at Week 8; D-VMP: Day 4 of Cycles 1 and 2 and post treatment at Week 8; D-Rd and D-Kd: Day 4 of Cycles 1 and 3 and post treatment at Week 8
- description
- Percentage of Participants with IRRs were reported. The administration-related systemic reactions are referred to as IRRs.
- measure
- Percentage of Participants With Infusion-Related Reactions (IRRs)
- time Frame
- For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
- description
- VGPR or better rate was defined as the percentage of participants who achieved VGPR or CR (including sCR) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.
- measure
- D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response
- time Frame
- From baseline up to 2 years 7 months
- description
- ORR was defined as the percentage of participants who achieved a PR or better, IMWG criteria, during the study or during follow up. IMWG criteria for PR \>= 50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.
- measure
- D-VRd Cohort: Overall Response Rate (ORR)
- time Frame
- Up to 2 years and 3 months
- description
- CR or better rate was defined as the percentage of participants with a CR or better response (that is, CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow; sCR: CR plus normal FLC ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.
- measure
- Percentage of Participants With CR or Better Response
- time Frame
- For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
- description
- DOR was defined as the time from the date of initial documented response (PR or better response) to the date of first documented evidence of progressive disease (PD) or death due to PD. PD is defined as an increase of 25% from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>=0.5 gram per deciliter \[g/dL\] and \>=200 mg/24 hours respectively); only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \>10 mg/dL); definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
- measure
- D-VMP, D-Rd and D-Kd Cohorts: Duration of Response (DOR)
- time Frame
- From baseline up to 2 years 7 months
- description
- Percentage of participants with antibodies to daratumumab were reported.
- measure
- Percentage of Participants With Anti-Daratumumab Antibodies
- time Frame
- For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
- description
- Percentage of participants with antibodies to rHuPH20 were reported.
- measure
- Percentage of Participants With Anti-rHuPH20 Antibodies
- time Frame
- For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
- description
- MRD negativity rate was defined as the percentage of participants who were considered MRD negative after MRD testing at any timepoint after the first dose by bone marrow aspirate. MRD negativity rate was assessed by next-generation sequencing at a threshold of \<10\^5.
- measure
- D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With Minimal Residual Disease (MRD) Negative Rate
- time Frame
- Up to 2 years and 3 months
Full study description
- brief Summary
- The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate.
- detailed Description
- The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected for albumin. Safety will be measured by adverse events, laboratory test results, electrocardiogram (ECGs), vital sign measurements, physical examination findings, SC injection-site assessments, and assessment of Eastern Cooperative Oncology Group (ECOG) performance status score. Study will consist of 3 phases (screening, treatment and follow-up) and duration of study is approximately 3 years.
Source references
- references
- citation
- Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosinol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33. doi: 10.1038/s41408-023-00805-x. No abstract available.
- pmid
- 36882409
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-0703d455fddb9c780259
- requested nct id
- NCT03412565
- primary nct id
- NCT03412565
- source kind
- fda_spl_label
- source record id
- 600cd22c-3a74-442e-a65d-c06d47bb892a
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- 4d394a76d75200aee159082614b3d501b9c6838f754398c66788c624ee10ad3d
- payload
- application numbers
- NDA202714
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-0703d455fddb9c780259
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03412565
- occurrences
- context exact
- esponse Overall Response N with Response 69 ORR (%) (95% CI) 81% (71, 89) Response category, n (%) sCR 18 (21%) CR 12 (14%) VGPR 28 (33%) PR 11 (13%) PLEIADES (NCT03412565) The efficacy of Kyprolis with daratumumab and hyaluronidase-fihj plus dexamethasone (DKd) was evaluated in a single-arm cohort of PLEIADES, a multi-cohort, op
- end
- 27261
- exact text
- NCT03412565
- start
- 27250
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/9/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 600cd22c-3a74-442e-a65d-c06d47bb892a
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 533e8d120100fb7638069302bd4fbc18be2ae0694744e2a65f7519357dead3bc
- spl effective time
- 20250618
- spl set id
- ea66eb30-e665-4693-99a1-a9d3b4bbe2d6
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-e80312aaa72147012092
- requested nct id
- NCT03412565
- primary nct id
- NCT03412565
- source kind
- fda_spl_label
- source record id
- bf986b71-66e2-4883-9687-f340388abafe
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- eb4594bfc4b7da7cf920f2ddec68327735f843acb8421ce03bb929490f0e5f22
- payload
- application numbers
- BLA761145
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-e80312aaa72147012092
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03412565
- occurrences
- context exact
- for Autologous Stem Cell Transplant The efficacy of DARZALEX FASPRO with bortezomib, melphalan and prednisone was evaluated in a single-arm cohort of PLEIADES (NCT03412565), a multi-cohort, open-label trial. Eligible patients were required to have newly diagnosed multiple myeloma who are ineligible for transplant. Patients receiv
- end
- 9562
- exact text
- NCT03412565
- start
- 9551
- context exact
- de and Dexamethasone The efficacy of DARZALEX FASPRO with lenalidomide and dexamethasone (DARZALEX FASPRO-Rd) was evaluated in a single-arm cohort of PLEIADES (NCT03412565), a multi-cohort, open-label trial. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8, once eve
- end
- 11385
- exact text
- NCT03412565
- start
- 11374
- context exact
- mib and Dexamethasone The efficacy of DARZALEX FASPRO with carfilzomib and dexamethasone (DARZALEX FASPRO-Kd) was evaluated in a single-arm cohort of PLEIADES (NCT03412565), a multi-cohort, open-label trial. This cohort enrolled patients with relapsed or refractory multiple myeloma excluding patients with left ventricular ejectio
- end
- 16733
- exact text
- NCT03412565
- start
- 16722
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/42/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- bf986b71-66e2-4883-9687-f340388abafe
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- cc5c020d9f13beded270f36e3763e767d6921219b4599f8a768ee996df18e7de
- spl effective time
- 20260903
- spl set id
- 4bb241af-4299-4373-8762-2d6709515db0
Preserved source evidence · Not medical advice